A qualitative study that looks to better understand women’s use of the dapivirine ring in both ASPIRE and HOPE and if and how adherence patterns differ between ASPIRE, a placebo-controlled trial, and the HOPE open-label extension trial in which all women are offered the dapivirine ring, yet may choose not to accept it. MTN-032 will be conducted in two parts. Phase I, which began in June 2016, will involve up to 224 former ASPIRE participants who had been assigned to use the dapivirine ring who will take part in either a focus group or in-depth interview. Among those Phase I participants who opt to enroll in HOPE, approximately 84 will take part in a single in-depth interview in Phase 2. Researchers will be looking to understand the reasons women with varying levels of adherence in ASPIRE decide to enroll into HOPE, whether they choose to accept the ring and if and how knowing the ring’s efficacy has any bearing on both their intended and actual use. MTN-032 is being conducted at six of the 15 clinical research sites for ASPIRE and HOPE.